Qiagen and BD settle PCR patent lawsuit

By LabPulse.com staff writers

November 8, 2021 -- Qiagen and Becton Dickinson (BD) have reached a settlement in a patent infringement lawsuit involving polymerase chain reaction (PCR) tests that Qiagen had acquired with its purchase of NeuMoDx Molecular.

The lawsuit had been filed in the U.S. District Court for the District of Delaware and involved the NeuMoDx 96 and NeuMoDx 288 clinical PCR systems that Qiagen acquired with its purchase of NeuMoDx in 2020.

Under the settlement deal, all pending patent and nonpatent claims have been resolved between BD and Qiagen and the codefendants, who were former officers of NeuMoDx.

Additionally, BD will receive a one-time, lump-sum payment of $53 million. The settlement includes general releases of all parties with no admissions of wrongdoing.

Qiagen launches new tuberculosis test
Qiagen has launched a new test to detect tuberculosis (TB) infection, which also received a CE Mark.
Qiagen reaches biological sample milestone
Qiagen's consumables kits have now been used to process more than 3 billion biological samples. Furthermore, the company's next-generation sequencing...
Qiagen receives EUA for portable SARS-CoV-2 antigen test
Qiagen announced it has received an emergency use authorization (EUA) from the U.S. Food and Drug Administration for its QIAreach SARS-CoV-2 digital assay,...
Quidel recalls Lyra SARS-CoV-2 assay due to false-negative tests
Quidel is recalling its Lyra SARS-CoV-2 real-time reverse transcription polymerase chain reaction assay for detecting infection with SARS-CoV-2 due to...
Qiagen and Sysmex form strategic alliance
Qiagen announced it has entered a strategic alliance with partner Sysmex for the development and commercialization of next-generation sequencing products...

Copyright © 2021 LabPulse.com

Last Updated ls 11/8/2021 3:35:40 PM



Subscribe Today
Do you want to be a Microbiology Insider?

When LabPulse gets hot new information, our Insiders are the first to find out. Stay current in today's competitive market by receiving our exclusive free email updates.

Yes, Keep Me Current